Pharmaceutical formulation containing gelling agent
AssigneePurdue Pharma L.P.
InventorsCurtis Wright, Benjamin Oshlack, Christopher Breder
Life of this patent
Estimating the term…
Abstract
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Claims7
A controlled release oral solid dosage form comprising:
- (i) a first population of particles comprising dextroamphetamine or a pharmaceutically acceptable salt thereof and
- (ii) a second population of particles comprising polyethylene oxide,
- the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient,
- wherein
- the particles of the first population are free from polyethylene oxide,
- the particles of the second population are coated with a coating comprising a cellulose polymer or an acrylic polymer, and
- the coating and the particles of the second population are free from said dextroamphetamine or pharmaceutically acceptable salt thereof.
A controlled release oral solid dosage form comprising a capsule containing:
- (i) a first population of particles comprising dextroamphetamine or a pharmaceutically acceptable salt thereof and
- (ii) a second population of particles comprising polyethylene oxide,
- the dosage form providing a therapeutic effect for about 12 hours when orally administered to a human patient, wherein
- the particles of the second population are coated with a coating comprising a cellulose polymer or an acrylic polymer, and
- the coating and the particles of the second population are free from said dextroamphetamine or pharmaceutically acceptable salt thereof.
A controlled release oral solid dosage form comprising:
- (i) a first population of particles comprising dextroamphetamine or a pharmaceutically acceptable salt thereof and
- (ii) a second population of particles comprising polyethylene oxide,
- the dosage form providing a therapeutic effect for about 12 hours to about 24 hours when orally administered to a human patient,
- wherein
- the particles of the second population are coated with a coating comprising a cellulose polymer or an acrylic polymer,
- the particles of the first population are free from polyethylene oxide, and
- the coating and the particles of the second population are free from said dextroamphetamine or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.